# Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

> **NCT04862741** · PHASE1 · COMPLETED · sponsor: **Landos Biopharma Inc.** · enrollment: 39 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** NX-13 250mg IR
- **DRUG:** NX-13 500mg IR
- **DRUG:** NX-13 500mg MR
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04862741
- **Lead sponsor:** Landos Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-05
- **Primary completion:** 2022-06-17
- **Final completion:** 2022-10-05
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04862741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04862741, "Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04862741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*